Immune-profiling niche Impact Proteomics operates in immune profiling and antigen discovery, offering a specialized platform that could complement pharmaceutical and biotech partners pursuing immunotherapies, autoimmune disease research, and diagnostic tools.

NSF funding leverage Recent substantial grant support from the National Science Foundation signals validated tech potential and a track record of programmatic funding, which can be leveraged to approach grant-ready collaborations and co-development opportunities.

End-to-end service Beyond discovery, the company provides proteomic and multiomic sample preparation products and services, presenting multiple entry points for sales—from sensors and reagents to service-based collaborations with research institutes and CROs.

Growth through partnerships With revenues in the low-to-mid seven-figure range and a clearly defined platform, there is potential to pursue tiered partnerships with larger CROs and biotech players seeking rapid antigen discovery capabilities and novel biomarkers.

Small team, agile model Single-employee footprint suggests high agility; opportunities exist to position as a nimble collaborator for pilot projects, technology licensing, or contract-based product development with larger life sciences organizations.